Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Dhimant R. Patel

Hematology Oncology | Hematology | Oncology
Bozeman Health Deaconess Hospital
931 Highland Blvd, Suite 3130, 
Bozeman, MT 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Bozeman Health Deaconess Hospital
931 Highland Blvd, Suite 3130, 
Bozeman, MT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dhimant Patel is a Hematologist Oncology specialist and a Hematologist in Bozeman, Montana. Dr. Patel is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Acute Hepatic Porphyria (AHP), Porphyria, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL). Dr. Patel is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WI
Hospital Affiliations
Bozeman Health Deaconess Hospital
Livingston Healthcare
Languages Spoken
English
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Network Health
  • HMO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

BOZEMAN HEALTH DEACONESS HOSPITAL
931 Highland Blvd, Suite 3130, Bozeman, MT 59715
Call: 406-414-5070

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Afatinib Dimaleate, Cetuximab
Study Phase: Phase 2/Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
View 4 Less Clinical Trials

3 Total Publications

New Landscape: Physician Compensation.
New Landscape: Physician Compensation.
Journal: JCO oncology practice
Published: December 22, 2020
View All 3 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kenneth F. May
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kenneth F. May
Oncology

Bozeman Health Deaconess Hospital

931 Highland Blvd, Suite 3130, 
Bozeman, MT 
 (0.1 miles away)
406-414-5070
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kenneth May is an Oncologist in Bozeman, Montana. Dr. May is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Neuroendocrine Tumor, Angiosarcoma, Inflammatory Breast Cancer, and Large-Cell Immunoblastic Lymphoma. Dr. May is currently accepting new patients.

Experienced in WT1-Related Wilms Tumor Syndromes
Dr. William A. Conkright
Hematology Oncology | Hematology | Oncology
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. William A. Conkright
Hematology Oncology | Hematology | Oncology

Bozeman Health Deaconess Hospital

915 Highland Blvd, 
Bozeman, MT 
 (0.1 miles away)
406-414-5000
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

William Conkright is a Hematologist Oncology specialist and a Hematologist in Bozeman, Montana. Dr. Conkright is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), Immune Thrombocytopenic Purpura (ITP), and Adult Immune Thrombocytopenia.

Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Courtney K. Regan-Wagner
Hematology Oncology | Hematology | Oncology
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Courtney K. Regan-Wagner
Hematology Oncology | Hematology | Oncology

Bozeman Health Deaconess Hospital

931 Highland Blvd, Suite 3130, 
Bozeman, MT 
 (0.1 miles away)
406-414-5070
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Courtney Regan-Wagner is a Hematologist Oncology specialist and a Hematologist in Bozeman, Montana. Dr. Regan-Wagner is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Neuroendocrine Tumor, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Bone Marrow Aspiration.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patel's expertise for a condition
ConditionClose
      • Advanced
      • Acute Hepatic Porphyria (AHP)
        Dr. Patel is
        Advanced
        . Learn about Acute Hepatic Porphyria (AHP).
        See more Acute Hepatic Porphyria (AHP) experts
      • Porphyria
        Dr. Patel is
        Advanced
        . Learn about Porphyria.
        See more Porphyria experts
      • Experienced
      • Acute Eosinophilic Pneumonia
        Dr. Patel is
        Experienced
        . Learn about Acute Eosinophilic Pneumonia.
        See more Acute Eosinophilic Pneumonia experts
      • Acute Mountain Sickness
        Dr. Patel is
        Experienced
        . Learn about Acute Mountain Sickness.
        See more Acute Mountain Sickness experts
      • Adult Immune Thrombocytopenia
        Dr. Patel is
        Experienced
        . Learn about Adult Immune Thrombocytopenia.
        See more Adult Immune Thrombocytopenia experts
      • Adult Soft Tissue Sarcoma
        Dr. Patel is
        Experienced
        . Learn about Adult Soft Tissue Sarcoma.
        See more Adult Soft Tissue Sarcoma experts
      • ALK-Positive Non-Small Cell Lung Cancer
        Dr. Patel is
        Experienced
        . Learn about ALK-Positive Non-Small Cell Lung Cancer.
        See more ALK-Positive Non-Small Cell Lung Cancer experts
      • Alveolar Soft Part Sarcoma
        Dr. Patel is
        Experienced
        . Learn about Alveolar Soft Part Sarcoma.
        See more Alveolar Soft Part Sarcoma experts
      View All 94 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2025 All Rights Reserved